LONDON, UK: ImmuPharma Plc, the specialist drug discovery and development company, has signed a 2-year collaboration agreement with Imperial College London.
Under the collaboration, Imperial College will provide significant intellectual input and guidance on a number of innovative peptide assets being developed at the R&D subsidiary, ImmuPharma Biotech in Bordeaux.
Dr Tim Franklin, Chief Operating Officer of ImmuPharma, added: “We are all extremely excited to be working with such a world leading academic institute. This union will be invaluable in guiding and progressing our earlier stage product development portfolio, as well as enhancing our intellectual property base.”
Dr Sébastien Goudreau, Chief Executive Officer of ImmuPharma Biotech, added: “We are delighted that now with the full support from the new Board for our innovative research programs, we have the opportunity of working with collaboration partners which include world leading academic institutes such as Imperial College London.”